Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,188 Shares of Stock
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,188 Shares of Stock
Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) insider Derek J. Maetzold sold 2,188 shares of the company's stock in a transaction on Monday, September 26th. The stock was sold at an average price of $23.93, for a total value of $52,358.84. Following the sale, the insider now owns 306,075 shares of the company's stock, valued at $7,324,374.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
城堡生物科学公司(纳斯达克代码:CSTL-GET Rating)内部人士德里克·J·梅佐尔德在9月26日(星期一)的一笔交易中出售了2,188股该公司股票。这只股票的平均售价为23.93美元,总价值为52,358.84美元。出售后,这位内部人士现在拥有306,075股该公司股票,价值7,324,374.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接.
Castle Biosciences Stock Performance
城堡生物科学公司股票表现
Shares of NASDAQ CSTL traded up $2.31 during midday trading on Wednesday, hitting $26.09. The stock had a trading volume of 246,420 shares, compared to its average volume of 284,220. The stock has a 50 day simple moving average of $28.95 and a 200-day simple moving average of $27.40. Castle Biosciences, Inc. has a 1 year low of $15.58 and a 1 year high of $68.65.
周三午盘,纳斯达克中国科技股份有限公司股价上涨2.31美元,至26.09美元。该股成交量为264,420股,而其平均成交量为284,220股。该股的50日简单移动均线切入位为28.95美元,200日简单移动均线切入位为27.40美元。Castle Biosciences,Inc.的一年低点为15.58美元,一年高位为68.65美元。
Castle Biosciences (NASDAQ:CSTL – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.52. The company had revenue of $34.84 million during the quarter, compared to analysts' expectations of $28.40 million. Castle Biosciences had a negative return on equity of 9.81% and a negative net margin of 40.37%. During the same quarter last year, the firm earned ($0.34) earnings per share. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post -2.81 EPS for the current fiscal year.
城堡生物科学公司(纳斯达克代码:CSTL-GET Rating)最近一次公布财报是在8月8日星期一。该公司公布了该季度每股收益(EPS)(0.06美元),比普遍预期的(0.58美元)高出0.52美元。该公司本季度营收为3,484万美元,高于分析师预期的2,840万美元。Castle Biosciences的净资产回报率为负9.81%,净利润率为负40.37%。去年同一季度,该公司每股收益为0.34美元。作为一个整体,股票研究分析师预计Castle Biosciences,Inc.将公布本财年每股收益为2.81美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC purchased a new position in Castle Biosciences in the first quarter valued at $57,000. Captrust Financial Advisors lifted its holdings in Castle Biosciences by 762.2% during the 2nd quarter. Captrust Financial Advisors now owns 4,018 shares of the company's stock worth $88,000 after buying an additional 3,552 shares during the last quarter. Amalgamated Bank purchased a new stake in Castle Biosciences during the 1st quarter worth about $152,000. PNC Financial Services Group Inc. lifted its holdings in Castle Biosciences by 52.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,745 shares of the company's stock worth $168,000 after buying an additional 1,290 shares during the last quarter. Finally, First Bank & Trust lifted its holdings in Castle Biosciences by 90.2% during the 2nd quarter. First Bank & Trust now owns 7,818 shares of the company's stock worth $172,000 after buying an additional 3,708 shares during the last quarter. 86.08% of the stock is currently owned by hedge funds and other institutional investors.
对冲基金和其他机构投资者最近买卖了该股的股票。Lazard Asset Management LLC在第一季度收购了Castle Biosciences的一个新头寸,价值5.7万美元。CapTrust Financial Advisors在第二季度增持了Castle Biosciences 762.2%的股份。CapTrust Financial Advisors现在持有该公司4,018股股票,价值8.8万美元,上个季度又购买了3,552股。合并银行在第一季度购买了Castle Biosciences的新股份,价值约15.2万美元。PNC金融服务集团(PNC Financial Services Group Inc.)在第一季度增持了Castle Biosciences 52.5%的股份。PNC金融服务集团现在持有该公司3,745股股票,价值16.8万美元,在上个季度又购买了1,290股。最后,First Bank&Trust在第二季度增持了90.2%的Castle Biosciences股份。First Bank&Trust现在持有该公司7818股股票,价值17.2万美元,在上个季度又购买了3708股。86.08%的股票目前由对冲基金和其他机构投资者持有。
Castle Biosciences Company Profile
城堡生物科学公司简介
(Get Rating)
(获取评级)
Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
Castle Biosciences,Inc.是一家商业阶段的诊断公司,专注于为皮肤癌提供诊断和预后检测服务。它的主要产品是DecisionDx-黑色素瘤,这是一种多基因表达谱(GEP)测试,用于确定被诊断为侵袭性皮肤黑色素瘤的患者的转移风险。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Castle Biosciences (CSTL)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- 免费获取StockNews.com关于城堡生物科学的研究报告(CSTL)
- 联合天然食品能同时对抗通胀和美联储吗?
- 马伦汽车已做好准备投入使用
- 饼干桶:可口的款待还是坏苹果?
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
收到《城堡生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Castle Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。